Keytruda’s Triumph in Early-Stage Triple-Negative Breast Cancer: A New Standard of Care
Keytruda’s Triumph in Early-Stage Triple-Negative Breast Cancer: A New Standard of Care Merck’s Keytruda (pembrolizumab) has achieved a significant milestone in the fight against early-stage triple-negative breast cancer (TNBC), with new data demonstrating a substantial improvement in overall survival rates. This development follows an earlier controversy over its approval based on preliminary endpoints. At the…






